Welcome
Support Centre
21 March 2013 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Evaluation and refinement of pandemic inFLUenza Community Assessment Tools
ISRCTN ISRCTN87130712
DOI 10.1186/ISRCTN87130712
ClinicalTrials.gov identifier
EudraCT number
Public title Evaluation and refinement of pandemic inFLUenza Community Assessment Tools
Scientific title Real time refinement and validation of criteria and tools used in primary care to aid hospital referral decisions for patients of all ages in the event of surge during an influenza pandemic
Acronym FLU-CATs
Serial number at source HTA: 11/46/22
Study hypothesis Assessment, refinement and validation of triage tools to guide GP referral of patients with influenza like illness during a pandemic in readiness for use should widespread illness exceed health care capacity (surge).

More details can be found at: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=12827
Lay summary Background and study aims
Flu pandemics occurs when a new flu virus emerges, rapidly spreads and causes widespread disease in many communities in many continents. Fortunately severe pandemics are rare events. When they occur health care capacity both in the community and hospitals can be overwhelmed. When this happens doctors need to make difficult decisions about who should be admitted to hospital and who can safely be allowed to stay at home.
To do this fairly, most doctors feel that the same types of patient assessments and questions should be used across the wider community. This process is called triage. The ethical principle of "triage" is to do most for most in a fair way. This does not mean treating everybody equally. It means using scarce resources for those people most likely to benefit from treatment.
Triage tools should help doctors identify which people are most likely to benefit from treatments only available in hospital and which people can safely be managed at home.The difficulty in designing triage tools for a future flu pandemic is that the exact nature of disease caused by a pandemic virus is generally unknown until that pandemic occurs. A further difficulty is that flu can affect children and adults quite differently. A one-size-fits-all tool is unlikely to work.
This study will develop processes that will test how parts of a general practitioner's questions and assessment of children and adults with flu like illness can predict who: can safely be kept at home; need hospital admission; need high dependency or intensive care; are most at-risk of dying.
The study uses the General Practitioner's (GP's) routine electronic record to capture most of the information and links
to the hospital record if the patient is admitted to hospital. These records are be accessed by researchers without revealing people’s identities at the Clinical Practice Research Datalink, which is part of the Medicines and Healthcare products Regulatory Authority (MHRA).
We will develop technology that allows records from about 600 GP surgeries across the UK to be studied automatically every week. This is quite complicated and needs to be set up in advance by working closely with the GPs that will ultimately use these tools. This first part of the study is called feasibility and pilot work.
In the event of a pandemic, the processes that have been developed will "go-live" and allow us to refine triage tools and check that they are "fit-for-purpose" in readiness for use should a pandemic become severe.

Who can participate?
People of all ages presenting to General Practitioners with Influenza Like Illness.

What does the study involve?
The study will be invisible to patients. GPs will be asked to record their routine consultations in a structured manner.

What are the possible benefits and risks of participating?
There are no immediate benefits or risks to patients. It would be reasonable to expect that participating GPs will develop a more structured approach to the assessment of patients presenting with Influenza Like Illness, and this may benefit patients. The knowledge and tools that evolve from this study will allow GPs and others to make better decisions about
managing people with influenza like illness, particularly if the event of a severe influenza pandemic.

Where is the study run from?
This is a collaboration between researchers working at The University of Liverpool, The University of Nottingham, and the Clinical Practice Research Datalink, MHRA, London.

When is the study starting and how long is it expected to run for?
We anticipate that the study will start in January 2013 and run for a total of 30 months.

Who is funding the study?
The study is funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme.

Who is the main contact?
Dr MG (Calum) Semple
m.g.semple@liverpool.ac.uk
Ethics approval Independent Scientific Advisory Committee for MHRA database research (ISAC), 29 May 2012, ref: 12_043R
Study design Prospective observational analysis
Countries of recruitment United Kingdom
Disease/condition/study domain Influenza like illness, influenza, seasonal influenza, pandemic influenza
Participants - inclusion criteria All people of all ages presenting to primary care general practitioners with influenza like illness
Participants - exclusion criteria Does not meet inclusion criteria
Anticipated start date 01/01/2013
Anticipated end date 01/07/2015
Status of trial Ongoing
Patient information material There is no patient information leaflet. There is no requirement for consent on recruitment. The study uses anonymised data harvested from routine consultations recorded by GPs in electronic health care records.
Target number of participants An estimate for sample size is 150 case, but there is no minimum or maximum limit
Interventions This is an observational study using anonymised data harvested from the electronic records of routine general practice consultations.
Primary outcome measure(s) 1. Hospital admission within 24 hours of GP assessment
2. Death within 30 days of GP assessment (all causes)
Secondary outcome measure(s) 1. GP’s decision to refer for hospital admission
2. Any need for augmented level of care during hospital admission i.e. level 2 – High Dependency and level 3 – Intensive/Critical Care, accepting that there are minor differences between paediatric and adult definitions of levels of care
3. Length of hospital stay (stratified >48 hours, ≥6 days & ≥12 days)
Sources of funding NIHR Health Technology Assessment - HTA (UK) ref:11/46/22
Trial website
Publications
Contact name Dr  Malcolm  Semple
  Address Institute of Child Health
University of Liverpool
Alder Hey Children's Hospital
Eaton Road
  City/town Liverpool
  Zip/Postcode L12 2AP
  Country United Kingdom
  Tel +44 (0)151 252 5440
  Email m.g.semple@liverpool.ac.uk
Sponsor University of Liverpool (UK)
  Address c/o David McVey
Senior Contracts Officer
Legal, Risk & Compliance
The Waterhouse Building, Block C
  City/town Liverpool
  Zip/Postcode L69 3BX
  Country United Kingdom
  Tel +44 (0)151 794 8792
  Email dmcvey@liv.ac.uk
  Sponsor website: http://www.liv.ac.uk/obchildhe/
Date applied 07/12/2012
Last edited 04/01/2013
Date ISRCTN assigned 12/12/2012
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2013 ISRCTN unless otherwise stated.